Newtown, Pa.-based Helius said it plans to use the proceeds from the 6.6-million-share flotation to complete a trial of the PoNS therapy in treating mild to moderate brain injury and the launch of a new trial in multiple sclerosis and another in cognition. The proceeds are also earmarked for R&D to complete an FDA submission, the company said.
Last year Helius closed an $8.1 million round. Last week, the company touted results from a pilot study in MS showing that patients treated with the PoNS device showed significant improvement in sensory organization tests, with functional-MRI scans showing significant blood oxygen level-dependent signal changes in the left primary motor cortex.
($1 = C$1.30514)
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.